Clinical trial NCT05653037: A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects
Official title: A Randomized, Single-blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Suzhou Ribo Life Science Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2022-12-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a Randomized, Single-blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects. The study will be performed in single ascending dose (SAD) phase in healthy subjects. The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information and PK/PD data in each cohort.

RBD4059, a GalNAc conjugated siRNA, is an FXI-targeted new molecular entity independently developed by Ribo using its proprietary siRNA delivery system - RIBO-GalSTARTM.

Detailed description: RBD4059, a GalNAc conjugated siRNA, is an FXI-targeted new molecular entity independently developed by Ribo using its proprietary siRNA delivery system - RIBO-GalSTARTM. As a GalNAc-based liver targeting delivery system, RIBO-GalSTARTM incorporates a unique technology for the delivery of oligonucleotide therapeutics for various targets and indications associated with the liver, thus enabling highly specific and highly durable enrichment of the siRNA in hepatocytes, the primary source of FXI. RBD4059 is, therefore, proposed to be a novel effective and durable antithrombotic treatment, with low bleeding risk via inhibition of FXI activity and prolongation of APTT.

Eligibility criteria: Inclusion Criteria:

* Male and female (non-childbearing potential only), aged 18 to 65 years, inclusive.
* Body mass index (BMI) between 18 and 32 kg/m2, inclusive.
* APTT, Prothrombin time(PT), INR, thrombin time (TT)，FXI activity must be within the normal reference range (as per the local laboratory reference range) at screening .
* Adequate complete blood counts (CBCs) and platelet are within the normal reference range (If CBCs are outside the reference range, unless not clinically significant determined by the Investigator ).
* Healthy as determined by pre-study medical history, vital signs, physical examination, clinical laboratory assessments, and 12-lead electrocardiogram (ECG).
* Subjects who are willing to cooperate with the study staff, comply with the study requirements, complete the study according to the relevant procedures specified in the protocol, and correctly understand and sign the informed consent form in writing.

Exclusion Criteria:

* Any uncontrolled or serious disease that may interfere with participation in the clinical study and/or put the subject at significant risk (according to Investigator's judgment) if he/she participates in the clinical study.
* History or presence of cardiovascular disease (including peripheral artery and cerebrovascular disease).
* Systolic blood pressure (SBP) is less than 90 or greater than 140 mmHg and/or diastolic blood pressure (DBP) is less than 40 or greater than 90 mmHg after 10 minutes of supine rest, unless determined by the Investigator to be not clinically significant.
* Diagnosis of diabetes mellitus, history of gestational diabetes that is fully resolved is not permitted.
* Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.

Note: additional inclusion/exclusion criteria may apply, per protocol.

Primary outcomes:
measure: Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0
timeFrame: SAD: Up to Day 169 ;
Secondary outcomes:
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:Cmax
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:Tmax
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:AUC0-t
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:AUC0-inf
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:t1/2
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:MRT
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:λz
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:CL/F
timeFrame: Up to 48 hours post-dose
measure: To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:Vz
timeFrame: Up to 48 hours post-dose
measure: To evaluate the pharmacodynamics (PD) effect of RBD4059 on levels of Coagulation factor XI (FXI) antigen in healthy subjects.
timeFrame: SAD: Up to Day 169 ;
measure: To evaluate the pharmacodynamics (PD) effect of RBD4059 on levels of FXI activity in healthy subjects.
timeFrame: SAD: Up to Day 169 ;
measure: To evaluate the pharmacodynamics (PD) effect of RBD4059 on levels of Activated partial thromboplastin time (APTT) in healthy subjects.
timeFrame: SAD: Up to Day 169 ;
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: Q-Pharm Pty Limited
Study officials:
References: